Money moves in silence. Download 2025 State of Venture Report: a data-driven analysis of active funds, unicorn, and family offices
About usSign in
Status
ACTIVE
Global HQ
New York, United States
Countries of investment
  • USA Canada
Investment stages
  • Seed
  • Series A
Industries
  • Biotechnology
  • Health Tech
  • AI
About
ExSight Ventures is a mission-focused venture capital firm investing in early-stage ophthalmic solutions, led by retinal surgeons to bridge the funding gap in life sciences.
Min check size
$250K
Max check size
$4M
Fund size
NPS

Investment Thesis

ExSight Ventures invests in early stage ophthalmic diagnostic and treatment solutions to address the lack of early stage funding available to life science companies, relying on deep domain expertise in ophthalmology.
Lead investor
Co Invest
Number of exits
Preferred contact method

Manager's Experience

With a robust track record in venture capital, the fund manager has executed over 50 deals primarily in the technology and healthcare sectors. Their investment strategy emphasizes a data-driven approach, focusing on early to growth-stage opportunities across North America and Europe. Notable exits from their portfolio have significantly contributed to their reputation in the industry. Leveraging deep operational insights, the manager actively identifies thematic trends that drive innovation and value creation.

ExSight Ventures Contacts Information

Primary contact

Team

James Murray

Portfolio

ELIOS Vision

Re-Vana Therapeutics

Horizon Surgical Systems

DTx Pharma (acquired by Novartis)

Trefoil Therapeutics

Qura

Envision Diagnostics

2C Tech Corporation

ONL Therapeutics

RetroSense Therapeutics (acquired by Allergan)

LensGen

Valitor Bio

Novai.

Fund number
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp